← Leaderboards
Brian J Thomas
University Of Missouri-Columbia
$128,574
Attributed
$128,574
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $60.5K · FY2023–25$100K$75K$50K$25K$0
'23
'24
'25
Funding mix
By agency
NIH$128,574 · 1
By mechanism
F30$128,574 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Shi-Jie Chen$7,221,533
- Xiaoqin Zou$6,077,987
- David C Geary$7,986,103
- Jerod Skyberg$3,923,313
- Helen B Mullen$5,704,365
Others in their field
Other Rising Stars on “Adjuvant”
- Warwick Britton · University Of Sydney$10,964,476
- Philip Felgner · University Of California-Irvine$10,234,165
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Li Liang · University Of California-Irvine$7,511,446
- Bruxanne El-Kammash · University Of Chicago$7,281,050
- Nicolas Collins · Vaccine Formulation Institute (Ch) Ltd$6,937,118
Research focus
AdjuvantAdverse EventAffectAffinityAntibodiesAnti-CancerAntigen PresentationAnti-Tumor Immune ResponseAntitumor ResponseAptamerAptamer TechnologyAttentionAutomobile DrivingBindingBiodistributionBiological ProductsBispecific AntibodiesBurden Of IllnessBypassCancer BiologyCancer CellCancer PatientCancer SubtypesAdenocarcinoma
Grant awards (4)
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer$57,538
F30 · FY2025 · CA · contact PI
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer$3,000
F30 · FY2025 · CA · contact PI
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer$34,658
F30 · FY2024 · CA · contact PI
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer$33,378
F30 · FY2023 · CA · contact PI